RT Journal Article
SR Electronic
T1 Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.27.20028530
DO 10.1101/2020.02.27.20028530
A1 Chen, Dong
A1 Li, Xiaokun
A1 Song, Qifa
A1 Hu, Chenchan
A1 Su, Feifei
A1 Dai, Jianyi
A1 Ye, Yinghai
A1 Huang, Jianping
A1 Zhang, Xiaoming
YR 2020
UL http://medrxiv.org/content/early/2020/02/29/2020.02.27.20028530.abstract
AB BACKGROUND SARS-CoV-2 has caused a series of COVID-19 globally. SARS-CoV-2 binds angiotensin I converting enzyme 2 (ACE2) of renin–angiotensin system (RAS) and causes prevalent hypokalemiaMETHODS The patients with COVID-19 were classified into severe hypokalemia, hypokalemia, and normokalemia group. The study aimed to determine the relationship between hypokalemia and clinical features, the underlying causes and clinical implications of hypokalemia.RESULTS By Feb 15, 2020, 175 patients with COVID-19 (92 women and 83 men; median age, 46 [IQR, 34–54] years) were admitted to hospital in Wenzhou, China, consisting 39 severe hypokalemia-, 69 hypokalemia-, and 67 normokalemia patients. Gastrointestinal symptoms were not associated with hypokalemia among 108 hypokalemia patients (P > 0.05). Body temperature, CK, CK-MB, LDH, and CRP were significantly associated with the severity of hypokalemia (P<0.01). 93% of severe and critically ill patients had hypokalemia which was most common among elevated CK, CK-MB, LDH, and CRP. Urine K+ loss was the primary cause of hypokalemia. 1 severe hypokalemia patients was given 3 g/day, adding up to an average of 34 (SD=4) g potassium during hospital stay. The exciting finding was that patients responded well to K+ supplements when they were inclined to recovery.CONCLUSIONS Hypokalemia is prevailing in patients with COVID-19. The correction of hypokalemia is challenging because of continuous renal K+ loss resulting from the degradation of ACE2. The end of urine K+ loss indicates a good prognosis and may be a reliable, in-time, and sensitive biomarker directly reflecting the end of adverse effect on RAS system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Key scientific and technological innovation projects of Wenzhou (ZY202004) and Natural Science Foundation of Ningbo (2017A610273). All authors declare no interest. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesYes. All data are included in the manuscript.